Soluble CTLA-4 in sera of patients with bronchial asthma

Journal of Asthma

Volumn 42, Issue 2, 2005, Pages 133-139

  Shi, Huan Zhong ^a   Xiao Yun, M O ^a   Zhong, Xiao Ning ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Asthma; Pathogenesis; sCTLA 4; Serum

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IMMUNOGLOBULIN E; PLASMA PROTEIN;

ADULT; ANTIGEN DETECTION; ARTICLE; ASTHMA; BLOOD GAS ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LEUKOCYTE COUNT; LUNG FUNCTION TEST; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PEAK EXPIRATORY FLOW; PROTEIN BLOOD LEVEL;

EID: 17644370003     PISSN: 02770903     EISSN: 15324303     Source Type: Journal    
DOI: 10.1081/JAS-51331     Document Type: Article

References (23)

1. Brunet JF, Denizot F, Luciani MF, Roux-Dosseto M, Suzan M, Mattei MG, Golstein P. A new member of the immunoglobulin superfamily - CTLA-4. Nature 1987; 328(6127):267-270.
2. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 1991; 174(3):561-569.
3. Krummel MF, Allison JP. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med 1996; 183(6):2533-2540.
4. Saverino D, Tenca C, Zarcone D, Merlo A, Megiovanni AM, Valle MT, Manca F, Grossi CE, Ciccone E. CTLA-4 (CD152) inhibits the specific lysis mediated by human cytolytic T lymphocytes in a clonally distributed fashion. J Immunol 1999; 162(2):651-658.
5. Carreno BM, Bennett F, Chau TA, Ling V, Luxenberg D, Jussif J, Baroja ML, Madrenas J. CTLA-4 (CD152) can inhibit T cell activation by two different mechanisms depending on its level of cell surface expression. J Immunol 2000; 165(3):1352-1356.
6. Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, Thompson CB, Griesser H, Mak TW. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science 1995; 270(5238):985-988.
7. Wardlaw AJ, Brightling CE, Green R, Woltmann G, Bradding P, Pavord ID. New insights into the relationship between airway inflammation and asthma. Clin Sci (Lond) 2002; 103(2):201-211.
8. Tattersfield AE, Knox AJ, Britton JR, Hall IP. Asthma. Lancet 2002; 360(9342):1313-1322.
9. Burr JS, Kimzey SL, Randolph DR, Green JM. CD28 and CTLA4 coordinately regulate airway inflammatory cell recruitment and T-helper cell differentiation after inhaled allergen. Am J Respir Cell Mol Biol 2001; 24(5):563-568.
10. Krinzman SJ, De Sanctis GT, Cernadas M, Mark D, Wang Y, Listman J, Kobzik L, Donovan C, Nassr K, Katona I, Christiani DC, Perkins DL, Finn PW. Inhibition of T cell costimulation abrogates airway hyperresponsiveness in a murine model. J Clin Invest 1996; 98(12):2693-2699.
11. Deurloo DT, van Esch BC, Hofstra CL, Nijkamp FP, van Oosterhout AJ. CTLA4-IgG reverses asthma manifestations in a mild but not in a more "severe" ongoing murine model. Am J Respir Cell Mol Biol 2001; 25(6):751-760.
12. Magistrelli G, Jeannin P, Herbault N, Benoit De Coignac A, Gauchat JF, Bonnefoy JY, Delneste Y. A soluble form of CTLA-4 generated by alternative splicing is expressed by nonstimulated human T cells. Eur J Immunol 1999; 29(11):3596-3602.
13. Oaks MK, Hallett KM. A soluble form of CTLA-4 in patients with autoimmune thyroid disease. J Immunol 2000; 164(10):5015-5018.
14. Lee SY, Lee YH, Shin C, Shim JJ, Kang KH, Yoo SH, In KH. Association of asthma severity and bronchial hyperresponsiveness with a polymorphism in the cytotoxic T-lymphocyte antigen-4 gene. Chest 2002; 122(1):171-176.
15. Aas K. Heterogeneity of bronchial asthma. Sub-populations-or different stages of the disease. Allergy 1981; 36(1):3-14.
16. Shi HZ, Xiao CQ, Zhong D, Qin SM, Liu Y, Liang GR, Xu H, Chen YQ, Long XM, Xie ZF. Effect of inhaled interleukin-5 on airway hyperreactivity and eosinophilia in asthmatics. Am J Respir Crit Care Med 1998; 157(1):204-209.
17. Kay AB. Allergy and allergic diseases: first of two parts. N Engl J Med 2001; 344(1):30-37.
18. Schwartz RH. A cell culture model for T lymphocyte clonal anergy. Science 1990; 248(4961):1349-1356.
19. June CH, Bluestone JA, Nadler LM, Thompson CB. The B7 and CD28 receptor families. Immunol. Today 1994; 15(7):321-331.
20. Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, Thompson CB, Bluestone JA. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994; 1(5):405-413.
21. Keane-Myers A, Gause WC, Linsley PS, Chen SJ, Wills-Karp M. B7-CD28/CTLA-4 costimulatory pathways are required for the development of T helper cell 2-mediated allergic airway responses to inhaled antigens. J Immunol 1997; 158(5):2042-2049.
22. Masteller EL, Chuang E, Mullen AC, Reiner SL, Thompson CB. Structural analysis of CTLA-4 function in vivo. J Immunol 2000; 164(10):5319-5327.
23. Oaks MK, Hallett KM, Penwell RT, Stauber EC, Warren SJ, Tector AJ. A native soluble form of CTLA-4. Cell Immunol 2000; 201(2): 144-153.